anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The microcirculation is altered in acute kidney injury and chronic kidney disease. The microcirculation is poor in end-stage renal disease patients receiving hemodialysis. Kidney transplant can improve the life quality of these patients. However, surgical stress and inflammatory response may cause microcirculatory dysfunction and intestinal injury. Moreover, the transplanted kidney would suffer from the ischemia and reperfusion injury, and it may result in acute kidney injury. In ischemia and reperfusion injury animal model, dexmedetomidine has been proven to attenuate kidney and intestinal injury. In our previous study of surgical stress and pain stimulation rat model, we found that dexmedetomidine attenuate the intestinal microcirculatory dysfunction. In patients receiving coronary artery bypass graft surgery, dexmedetomidine increases urine output and decreases postoperative serum level of neutrophil gelatinase-associated lipocalin. The aim of this study is to investigate whether perioperative dexmedetomidine infusion may attenuate microcirculatory dysfunction, kidney injury, and intestinal injury for patients undergoing kidney transplant.

This is a randomized, single-blind, prospective, controlled clinical trial. The patients will be randomly assigned to the control group or dexmedetomidine group. After induction of anesthesia, the patients in the control group will receive regular perioperative care. The patients in the dexmedetomidine group will receive perioperative dexmedetomidine continuous intravenous infusion after induction of anesthesia till 2 hours after the end of the operation. All patients will receive sublingual microcirculation examination, laboratory tests of blood urine nitrogen, creatinine, and enzyme-linked immunosorbent assays of serum level of endocan, diamine oxidase, and neutrophil gelatinase-associated lipocalin at preset time points. The urine level of neutrophil gelatinase-associated lipocalin will also be measured. The vital signs and urine output will be recorded. The difference between the two groups will be compared.
Evidence indicates that pediatric chronic health conditions (CHCs) often impair executive functioning (EF) and impaired EF undermines pediatric CHC management. This bidirectional relationship likely occurs due to biobehavioural and social-structural factors that serve to maintain this feedback loop. Specifically, biobehavioural research suggests that inflammation may sustain a feedback loop that links together increased CHC severity, challenges with EF, and lower engagement in health promoting behaviours. Experiencing social and environmental inequity also maintains pressure on this feedback loop as experiencing inequities is associated with greater inflammation, increased CHC severity, as well as challenges with EF and engagement in health promoting behaviours. Amidst this growing body of research, a model of biobehavioural and social-structural factors that centres inflammation and EF is warranted to better identify individual and structural targets to ameliorate the effects of CHCs on children, families, and society at large. This paper proposes this model, reviews relevant literature, and delineates actionable research and clinical implications.
1387929 Medicines comprising ion-exchange resins PHARMACIA AB 5 June 1972 [4 June 1971] 26106/72 Heading A5B [Also in Division C3] Pharmaceutical preparations useful in lowering the cholesterol content of blood comprise polymerisation product which contain residues of the diamine H 2 N(CH 2 ) 6 NH 2  (I) which residues are interconnected by bridges to form a three dimensional network, the bridges being bound to N atoms in the residues of I and comprise C 3-30  saturated aliphatic hydrocarbon chains substituted by at least one OH group and optionally broken by one or more oxygen atoms; the amino groups are present in a free form or as the cation portion of a non- toxic salt. The polymer is insoluble in water or other solvents but is capable of swelling in water to gel form, 1g. of the dry product in the form of an HCl salt in the presence of water swelling to at least 5 ml and at most 50 ml. The polymer is in grain form having a particle size of 1-1000Á and has an ionexchange capacity within the range 0.2-1 milliequivalents chloride ions, per 100g. of dry gel. A typical example is prepared by condensing hexamethylene diamine with epichlorhydrin by dispersion methods (see Division C3). The products may be administered orally either as such or suspended in liquids or in the form of granulates, tablets or capsules optionally in the presence of physiologically acceptable carriers.
The problem of chronic postoperative pain (CPP) has remained relevant over the past decades, despite the active development of anesthesiology and surgery. Existing approaches to the treatment of acute postoperative pain do not provide effective prevention of CPP. The analysis of the results of studies on this problem was carried out. It was shown that the introduction of an interdisciplinary transitional pain service in surgery allows to increase the effectiveness of prevention and treatment of CPP, accompanying patients with high risks of pain chronization at each stage of surgical treatment (surgery planning, perioperative and outpatient, after discharge up to full recovery after surgery). The interdisciplinary nature of the transitional pain service in surgery ensures the timeliness and multimodality of the pain treatment methods used. It can be concluded that the development of a transitional pain service is an optimal strategy for the prevention and treatment of CPP.
Receiving palbociclib 125 mg/day orally for 21 days followed by 7 day's rest, for four 28 day cycles, letrozole 2.5 mg/day orally for 16 weeks and trastuzumab 600 mg s.c. every 3 weeks for a total of 5 doses and pertuzumab 840 mg i.v. loading dose followed by 420 mg i.v. every 3 weeks for 5 doses.
PURPOSE:To provide a pain mitigating agent for ectopic calcification, containing 24,25-dihydroxycholecalciferol as an active component, having high safety, and applicable for a long period. CONSTITUTION:24,25-Dihydroxycholecalciferol (hereinafter called as the substance), preferably 24R,25-dihydroxycholecalciferol is used as a pain mitigating agent for ectopic calcification. There are many patients complaining the pain caused by the ectopic calcification near the joints or soft tissues as a complication of the long-term dialysis. It has been found that the substance is effective to mitigate the pain of ectopic calcification. It has extremely high safety. It is administered parenterally e.g. by peritoneal infusion, however, it can be administered orally. Dose: preferably 0.5-10,000mug daily.
PURPOSE: A digital questionnaire generation device and a method are provided to generate life log information reflecting a life habit of an examinee by using sensor information collected in a portable device of the examinee. CONSTITUTION: An information collection unit(131) collects biometric information for an examinee from a human body sensor. The information collection unit collects movement information or location information for the examinee from a movement sensor. An information analysis unit(132) generates health state information. An information conversion unit(133) generates life log information. An information display unit(135) displays a digital questionnaire. [Reference numerals] (131) Information collection unit; (132) Information analysis unit; (133) Information conversion unit; (134) Information link unit; (135) Information display unit
###  Teratogenic Effects: Pregnancy Category C

There are no adequate and well-controlled studies in pregnant women. Eszopiclone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Oral administration of eszopiclone to pregnant rats (62.5, 125, or 250 mg/kg/day) and rabbits (4, 8, or 16 mg/kg/day) throughout organogenesis showed no evidence of teratogenicity up to the highest doses tested. In rats, reduced fetal weight and increased incidences of skeletal variations and/or delayed ossification were observed at the mid and high doses. The no-observed-effect dose for adverse effects on embryofetal development is 200 times the maximum recommended human dose (MRHD) of 3 mg/day on a mg/m2 basis. No effects on embryofetal development were observed in rabbits; the highest dose tested is approximately 100 times the MRHD on a mg/m2 basis.

Oral administration of eszopiclone (60, 120, or 180 mg/kg/day) to pregnant rats throughout the pregnancy and lactation resulted in increased post-implantation loss, decreased postnatal pup weights and survival, and increased pup startle response at all doses. The lowest dose tested is approximately 200 times the MRHD on a mg/m2 basis. Eszopiclone had no effects on other developmental measures or reproductive function in the offspring.
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial hyperplasia, pannus formation, and cartilage and bone destruction. Lysine-specific demethylase 1 (LSD1), an enzyme involved in transcriptional regulation, has an unclear role in synovial inflammation, fibroblast-like synoviocytes migration, and invasion during RA pathogenesis. In this study, we observed increased LSD1 expression in RA synovial tissues and in TNF-α-stimulated MH7A cells. SP2509, an LSD1 antagonist, directly reduced LSD1 expression and reversed the elevated levels of proteins associated with inflammation, apoptosis, proliferation, and autophagy induced by TNF-α. Furthermore, SP2509 inhibited the migratory capacity of MH7A cells, which was enhanced by TNF-α. In CIA models, SP2509 treatment ameliorated RA development, reducing the expression of pro-inflammatory cytokines and alleviating joint pathological symptoms. These findings underscore the significance of LSD1 in RA and propose the therapeutic potential of SP2509.
Specific Aim 1: Determine the consequences of oxidative stress on skeletal muscle afferent feedback and muscle blood flow during exercise in hypertension. Hypothesis: Afferent feedback sensitivity, determined by passive leg movement (isolation of mechanoreceptor sensitivity) and post exercise circulatory occlusion (isolation of metaboreceptor sensitivity) will be greater in hypertension leading to the exaggerated EPR. Muscle blood flow, assessed by Doppler ultrasound during multiple exercise intensities, will be impaired in hypertension leading to exercise intolerance. Reductions in oxidative stress, achieved by an oral antioxidant treatment (Vitamins C, E and alpha lipoic acid), will reduce afferent fiber sensitivity and improve muscle blood flow in hypertension. Additionally, venous endothelial cells will express elevated markers of oxidative stress providing novel evidence that the vascular endothelium contributes to the greater oxidative stress in hypertension.
AIMS: Relationship between body mass index (BMI), frailty, and clinical adverse events remains unclear in patients with heart failure (HF) with preserved ejection fraction (HFpEF) in different patient populations. We aimed to compare the association of BMI, frailty, and clinical adverse events between a US cohort from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) study and a Chinese cohort from the Heart Failure Registry of Patient Outcomes (HERO) study.
METHODS AND RESULTS: We used data of 1715 participants enrolled from America in the TOPCAT study and 1487 patients with HFpEF in the Chinese registry study, the HERO. We evaluated the relationship between BMI and frailty using multivariate restricted cubic spline logistic regression. Association between frailty and BMI categories and primary outcomes including HF hospitalization, aborted sudden death, and cardiovascular death, all-cause mortality, and HF hospitalization were analysed by Cox proportional hazards models. The patients' mean age was 72 ± 11 years for both study populations, with 50% and 46% female for the TOPCAT study and the HERO study, respectively. Patients in the TOPCAT study had a higher mean BMI (33.9 vs. 24 kg/m2), with 72.3% vs. 52.9% defined as moderately to severely frail (frailty index > 0.3). In the TOPCAT study, risk of frailty rose as BMI increased, but not in the HERO study. Patients with frailty were at significant higher risk for the primary composite outcomes [hazard ratio (HR) 1.84 (95% confidence interval: 1.46-2.32)], all-cause mortality [HR 1.73 (1.34-2.25)], and HF hospitalization [HR 1.83 (1.40-2.40)] in the TOPCAT study. The corresponding numbers in the HERO study were 1.26 (1.01-1.57), 2.21 (1.45-3.35), and 1.15 (0.81-1.37), respectively. The association of frailty with clinical outcomes did not vary with BMI categories in the two studies.
CONCLUSIONS: BMI distribution and association between BMI and frailty risk were different between the two study populations. Frailty was associated with clinical adverse events and this association was consistent across different BMI categories in both studies.
The present invention provides a bile acid absorbent/adsorbent comprising as active ingredients a lactic acid bacterium having a property of incorporating bile acids into the cell in the presence of an oligosaccharide and of no releasing them out of the cells, and the oligosaccharide. The lactic acid bacterium includes  Lactobacillus salivarius  ssp.  salicinius  strain JCM1044,  Bifidobacterium breve  strain JCM1192, etc. The oligosaccharide includes raffinose, kestose, nystose, trehalose, etc. The bile acid adsorbent is in a form of oral formulation, or eatables and drinkables, etc. The bile acid absorbent/adsorbent can be utilized as cholesterol lowering agents or colorectal cancer inhibitors.
<P>PROBLEM TO BE SOLVED: To provide a hair-developing, growing and nourishing method using an extract of Fomes yucatensis, and to provide a new medicament usable therefor, and a cosmetic.  <P>SOLUTION: The medicament or the cosmetic containing the extract of the Fomes yucatensis is produced. The Fomes yucatensis (Sou-ou) used in the extract of the Fomes yucatensis can be either one of the wild one or the one sold at a general grocery store. The growth of the hair is promoted by administering the Fomes yucatensis to human beings or vertebrates except the human beings. The hair growth promotor is useful for promotion of hair-growth and hair-nourishment, prevention of depilation, promotion of hair restoration or promotion of hair development.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Disclosed is a compound, a medicament, and a pharmaceutical composition for treating inflammation induced autoimmune skin diseases, for example psoriasis. The compound is Nib1, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of a pharmaceutically acceptable salt thereof, or a crystal form thereof. the compound Nib1 has a chemical formula of C 28 H 29 F 2 N 3 O. It represents a new treatment mechanism and can effectively treat inflammation induced autoimmune skin diseases, for example, non-specific dermatitis such as psoriasis, with less side effects and convenient route of administration, achieving a balance between safety and effectiveness. The compounds can be used for a long time and improve the quality of life of patients. The compounds, medicament, and pharmaceutical compositions can significantly improve clinical symptoms of inflammation induced autoimmune skin diseases, such as non-specific dermatitis such as psoriasis, such as skin rash, skin peeling, skin thickening, and epidermal hyperplasia, improve blood vessel dilation, reduce immune cell infiltration, and etc.
The invention relates to a medicament for dysfunctional uterine bleeding. The medicament is prepared from the following Chinese medicinal plants such as Chinese angelica, India madder root, safflower, rhubarb, cornu cervi pantotrichum and the like. Vitality-stagnation and blood-stasis type uterine bleeding has the cardinal symptoms of purple black blood blocks, overmuch amount or overless amount, incessant bleeding, dark purple tongue bodies or petechia and ecchymosis on the tongue bodies, and hesitant pulse. The medicament has the effects of nourishing blood and calming liver, cooling blood and clearing heat, promoting blood circulation and stopping bleeding, reinforcing insufficiency and restoring, warming middle and governing blood, cooling blood and expelling stasis and the like, wherein blood is enriched to assist rooting and is hot and smooth to stop bleeding, accumulated blood is cleared to generate new blood, and vitality is strengthened to recover Yin blood. The medicament has a reasonable formula, is convenient to take, has a good curative effect, quickly cures diseases, and does not have any toxic or side effect. The whole formula is effective and has the effects of cooling blood, clearing away heat, activating blood, dissolving stasis, warming meridians to dissipate cold, and consolidating and regulating menstruation. The medicament has the effects of cooling blood and stopping bleeding without congestion, stopping metrorrhagia and metrostaxis, and making menstruation normal and healthy as usual. The medicament can cure the dysfunctional uterine bleeding of puberty patients and menopause patients in a short time. By the medicament, hundreds of patients are clinically treated for more than ten years, the cure rate is 93.8 percent and the total effective rate is 97.5 percent.
The physiologic assessment of coronary artery disease and ischemia-guided percutaneous coronary intervention (PCI) has become a standard practice for patients with coronary artery disease. Fractional flow reserve (FFR) represents hyperemic flow limitation caused by an epicardial coronary stenosis and its clinical usefulness has been proven by many clinical studies. However, the FFR is limited to clinical use despite the fact that it is recommended by the guideline due to the inconvenience of patients using medications used to induce maximum hyperemia, and the need for additional procedure time. Recently, a physiologic index which does not require hyperemia, instantaneous wave free ratio (iFR), was introduced and recent trials showed non-inferiority of iFR-guided strategy for 1-year clinical outcome, compared with FFR-guided strategy. Recently, not only iFR but also various intravascular pressure measurement techniques have been developed, one of which is diastolic hyperemia-free ratio (DFR). DFR uses the mean Pd/Pa calculated over the period in diastole defined as that during which arterial pressure is negatively sloped and below the mean arterial pressure. DFR showed equivalence as compared to gold standard FFR in the discrimination of non-culprit lesions requiring revascularization in patients with NSTEMI. In the case of DFR, there is no issue in terms of safety because it is conducted in the same way as iFR, but there are not many studies on the validation between DFR and FFR. Therefore, the present study aimed to identify the quality of concordance between DFR and FFR, determine the features associated with discrepancies in DFR and FFR.
Efforts have thus been made towards the discovery of the next generation of antibiotics to combat the antibiotic resistance in emerging bacterial strains. In spite of these efforts, there remains a need in the art for novel antibiotics and variations of existing antibiotics. For example, there is a need for low toxicity bearing compounds, which can be used for the treatment of vancomycin resistant as well as sensitive strains, with low molar concentrations as compared to vancomycin. The present invention provides compounds of formula (1), Wherein R a  has the meaning as defined in the claims. The present invention also relates to pharmaceutical composition comprising said compounds. The present invention also relates to said compound and pharmaceutical composition for use as an antibacterial compound.
The present invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of .beta.-D-mannuronic acid linked by 1,4 glycosidic bonds and shown on Formula II. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The present invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedures than an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2-6 and the temperature of 100-120°C, and pH is adjusted to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative degradation product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes. (see formula II)
This is a Phase III, double blind (neither investigator nor participant knows the treatment received), placebo-controlled (an inactive substance that is compared with the study medication to test whether the study medication has a real effect in clinical study), multicenter, 5-arm (treatment groups) study of golimumab at 2 doses (given with or without MTX over a period of 30 minutes) for at least 48 weeks in patients with active RA despite concurrent MTX therapy. The study consists of a treatment period of golimumab IV infusions (IV Period) which ranges from 48 weeks to approximately 140 weeks, assuming an enrollment period of approximately 92 weeks, and a long-term optional extension period (Extension Study) in which golimumab SC injections will be given for 24 weeks. The end of study will be the time the last participant completes the Week E-40 visit (Extension Study) for safety follow-up assessments. For the IV Period, participants will be randomly assigned to 1 of the 5 treatment groups in a 1:1:1:1:1 ratio (approximately 125 patients per group). At Week 16 and Week 24, joint assessment results will be used to allow participants to enter early escape and dose regimen adjustment, respectively, in a blinded fashion. Treatment will be unblinded after the 48-week database lock and participants will be given the option to participate in the Extension Study and receive SC injections of 50mg golimumab (with or without MTX) every 4 weeks for an additional 24 weeks. Safety will be monitored throughout the study. The entire study duration (IV Period plus Extension Study) for each participant will range from 88 weeks up to 192 weeks, assuming an enrollment period of approximately 92 weeks.
The present research focused on the effect of the age for the corneal biomechanics of low and moderate myopia patients after wearing orthokeratology (OK lens). According to age, the included cases were divided into 3 groups: Ⅰ (8-12 years old), Ⅱ (13-16 years old), Ⅲ (over 16 years old). The OK lenses used in the present study are of the same design (Euclid Systems Orthokeratology; Euclid System, Herndon, VA, USA). The base line (Day 0) and different follow-up time point (Day 1, Week 1, Week 2, Month 1, Month 3, and Month 6) of dynamic corneal response (DCR) (including 19 items) of the patients derived by Corvis ST were collected. The difference between before and after wearing OK Lens and the changes of parameters among the three groups were both analyzed. And the correlation between axis length (AL) and the 19 parameters also was analyzed. Through the analysis of corneal biomechanical parameters, further learn the influence of OK lens on the patient cornea. It would help ophthalmologist and optometrist find out the potential issue and reach a better control result.
Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. Intravenous (i.v.) trastuzumab 6 mg/kg on day 1 every 21 days.
Patients received 0.5mg/kg Ketanest®S during anesthesia induction period. Patients received 0.5mg/kg/h Ketanest®S during anesthesia maintenance period.